Rallybio (RLYB) News Today → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free RLYB Stock Alerts $1.84 +0.06 (+3.37%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 2:52 AM | americanbankingnews.comRallybio's (RLYB) Buy Rating Reaffirmed at HC WainwrightMay 12 at 5:58 AM | americanbankingnews.comShort Interest in Rallybio Co. (NASDAQ:RLYB) Drops By 33.8%May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio: Promising FNAIT Drug Candidate and Strong FinancialsMay 10, 2024 | marketbeat.comRallybio (NASDAQ:RLYB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Rallybio in a report on Friday.May 10, 2024 | markets.businessinsider.comRallybio’s Advancements and Financial Health Prompt a Buy Rating from Analyst Jonathan WollebenMay 9, 2024 | finance.yahoo.comRallybio Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | finance.yahoo.comRallybio to Present at the 2024 Citizens JMP Life Sciences ConferenceApril 29, 2024 | marketbeat.comabrdn plc Takes $4.13 Million Position in Rallybio Co. (NASDAQ:RLYB)abrdn plc purchased a new position in Rallybio Co. (NASDAQ:RLYB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,727,067 shares of the company's stock, valued at approximately $4,128,000. abrdnApril 28, 2024 | marketbeat.comShort Interest in Rallybio Co. (NASDAQ:RLYB) Increases By 126.0%Rallybio Co. (NASDAQ:RLYB - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 2,960,000 shares, an increase of 126.0% from the March 31st total of 1,310,000 shares. Approximately 17.2% of the company's stock are sold short. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is presently 1.9 days.April 23, 2024 | finance.yahoo.comFibroGen, Inc. (FGEN)April 18, 2024 | marketbeat.comRallybio's (RLYB) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and issued a $8.00 price objective on shares of Rallybio in a research note on Thursday.April 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT TreatmentApril 17, 2024 | msn.comRallybio (RLYB) Price Target Decreased by 16.00% to 12.85April 17, 2024 | businesswire.comFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingApril 14, 2024 | finance.yahoo.comCozad New Venture Challenge Demo Day awards student start-ups with fundingApril 12, 2024 | investing.comRallybio partners with Johnson & Johnson on FNAIT treatmentApril 11, 2024 | msn.comRare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots HigherApril 11, 2024 | proactiveinvestors.comRallybio partners with J&J to advance therapies targeting rare fetal diseaseApril 11, 2024 | marketbeat.comRallybio (NASDAQ:RLYB) PT Lowered to $11.00Wedbush reduced their target price on shares of Rallybio from $13.00 to $11.00 and set an "outperform" rating on the stock in a report on Thursday.April 11, 2024 | msn.comRallybio shares gain on investment from J&J for rare fetal condition treatmentApril 11, 2024 | investorplace.comWhy Is Rallybio (RLYB) Stock Up 93% Today?April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program ProgressApril 10, 2024 | businesswire.comRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)April 1, 2024 | finance.yahoo.comRallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual MeetingMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market PotentialMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial StabilityMarch 12, 2024 | benzinga.comRallybio: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comRallybio Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | businesswire.comRallybio to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 9, 2024 | marketbeat.comFY2023 Earnings Estimate for Rallybio Co. Issued By HC Wainwright (NASDAQ:RLYB)Rallybio Co. (NASDAQ:RLYB - Free Report) - Research analysts at HC Wainwright increased their FY2023 earnings per share estimates for shares of Rallybio in a research report issued to clients and investors on Wednesday, February 7th. HC Wainwright analyst M. Kapoor now expects that the company wiFebruary 8, 2024 | marketbeat.comFY2028 Earnings Estimate for Rallybio Co. Issued By Wedbush (NASDAQ:RLYB)Rallybio Co. (NASDAQ:RLYB - Free Report) - Research analysts at Wedbush issued their FY2028 earnings estimates for shares of Rallybio in a research report issued to clients and investors on Tuesday, February 6th. Wedbush analyst L. Chico expects that the company will earn ($0.88) per share for thFebruary 7, 2024 | msn.comJefferies cuts Rallybio to hold, cites lack of near-term catalystsFebruary 7, 2024 | msn.comRallybio Announces Workforce Reduction and Restructuring CostsFebruary 7, 2024 | marketbeat.comRallybio (NASDAQ:RLYB) Price Target Cut to $8.00JMP Securities lowered their price target on Rallybio from $16.00 to $8.00 and set a "market outperform" rating for the company in a research report on Wednesday.February 7, 2024 | markets.businessinsider.comRallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy RatingFebruary 6, 2024 | markets.businessinsider.comRallybio Announces Portfolio Prioritization Plan; To Reduce Workforce By 45%February 6, 2024 | msn.comMadrigal Pharmaceuticals, Cerus among healthcare moversFebruary 6, 2024 | marketwatch.comRallybio to Cut 45% of Staff in Portfolio PrioritizationFebruary 6, 2024 | msn.comRallybio shares jump 13% on restructuring, cash runway extensionFebruary 6, 2024 | finance.yahoo.comRallybio Announces Portfolio Prioritization and Provides Corporate UpdateFebruary 2, 2024 | msn.comCanada's economy likely grew in December, avoiding recessionJanuary 6, 2024 | markets.businessinsider.comRallybio’s Drug Pipeline Promises Breakthroughs in FNAIT and gMG Treatments: Kapoor Maintains Buy RatingJanuary 4, 2024 | finance.yahoo.comRallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024December 21, 2023 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Strong Phase 1b Results and Strategic FocusDecember 20, 2023 | finance.yahoo.comRallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5December 10, 2023 | businesswire.comRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65 th American Society of Hematology Annual MeetingDecember 9, 2023 | finance.yahoo.comRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual MeetingNovember 29, 2023 | markets.businessinsider.comBuy Rating Affirmed for Rallybio as RLYB212 Shows Promise in FNAIT Treatment AdvancementsNovember 28, 2023 | msn.comRallybio posts early Phase 1 data for lead candidate in bleeding disorderNovember 28, 2023 | finance.yahoo.comRallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. RLYB Media Mentions By Week RLYB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLYB News Sentiment▼0.740.56▲Average Medical News Sentiment RLYB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLYB Articles This Week▼101▲RLYB Articles Average Week Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Jaguar Health News Hookipa Pharma News Tempest Therapeutics News Assembly Biosciences News SCYNEXIS News vTv Therapeutics News Marinus Pharmaceuticals News InflaRx News SELLAS Life Sciences Group News Affimed News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLYB) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
